Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
S.-H.I. Ou(University of California, Irvine Medical Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Paulina Selaru(Pfizer (United States)), Yiyun Tang(Southwest University), Cynthia Huang Bartlett(Pfizer (United States)), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Pasi A. Jänne(Harvard University), D.-W. Kim(Seoul National University Hospital), Jeffrey W. Clark(Massachusetts General Hospital), D. P. Cohen(Pfizer (United States)), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 221
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k